NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

The inaugural TCCI AI-Driven Science Symposium was held in San Francisco from Monday to Tuesday, bringing together three ...

Ozempic, MRI machines and flat screen televisions all emerged out of fundamental research decades earlier — the very types of ...

Nex-z is one of two late-stage projects on the go at Intellia, a specialist in CRISPR gene-editing co-founded by Nobel Prize ...

Founded in 2018, Metagenomi is using a Nobel prize-winning approach developed by Jennifer Doudna and Emmanuelle Charpentier called CRISPR, which allows for the targeted editing of gene sequences.

Catherine Santino is a Style Writer-Reporter at PEOPLE. She began as a contributor for PEOPLE in 2022 and joined the staff full-time in 2024. Her work has previously appeared in The Zoe Report, ...

Jennifer Aniston has revealed how her approach to health and fitness has evolved. Supreme Court Is Told Trump Tariffs Are Illegal $3 Trillion Tax Why do Florida’s super speeders drive 100+? Here’s ...

Gene editing is now possible, and the underlying potential of the science is enormous -- just ask CRISPR Therapeutics. Share prices of electric vehicle maker BYD have struggled of late, but its ...